Confidence in Concept 2012 - Cambridge
Lead Research Organisation:
University of Cambridge
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
People |
ORCID iD |
Publications
Bally L
(2018)
Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care.
in The New England journal of medicine
Berends LM
(2013)
Catch-up growth following intra-uterine growth-restriction programmes an insulin-resistant phenotype in adipose tissue.
in International journal of obesity (2005)
Brame AL
(2015)
Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist.
in Hypertension (Dallas, Tex. : 1979)
Btesh J
(2013)
Mapping the binding site of TRPV1 on AKAP79: implications for inflammatory hyperalgesia.
in The Journal of neuroscience : the official journal of the Society for Neuroscience
Cimino I
(2022)
The role of GDF15 in food intake and appetitive behaviour
in Current Opinion in Endocrine and Metabolic Research
Davenport AP
(2018)
New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine.
in Physiological research
De La Fuente A
(2015)
Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation
in Journal of Cell Biology
Feig C
(2013)
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
in Proceedings of the National Academy of Sciences of the United States of America
Flint SM
(2016)
Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseases.
in RMD open
| Description | 'resistance starch productionspud project' |
| Amount | £53,918 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2019 |
| Description | 2014 Call for Proposals for research into Parkinson's disease |
| Amount | £100,000 (GBP) |
| Organisation | Addenbrooke's Charitable Trust (ACT) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 03/2018 |
| Description | Action of combination of peptide on the cardiovascular physio |
| Amount | £488,000 (GBP) |
| Organisation | AstraZeneca |
| Department | Astra Zeneca |
| Sector | Private |
| Country | United States |
| Start | 09/2016 |
| End | 09/2020 |
| Description | Action of combination of peptide on the cardiovascular physiology |
| Amount | £488,000 (GBP) |
| Organisation | Heptares Therapeutics Ltd |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | Apelin, relaxin and combination peptide effects on cardiovascular physiology |
| Amount | £244,603 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | CRUK CRT Award |
| Amount | £20,000 (GBP) |
| Organisation | Cancer Research Technology (CRT) |
| Sector | Private |
| Country | United Kingdom |
| Start | 04/2015 |
| End | 08/2015 |
| Description | Cambridge Enterprise -PoC |
| Amount | £91,000 (GBP) |
| Organisation | University of Cambridge |
| Department | Cambridge Enterprise |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Closed loop in young children - KidsAP |
| Amount | £1,399,846 (GBP) |
| Funding ID | 731560 |
| Organisation | European Commission H2020 |
| Sector | Public |
| Country | Belgium |
| Start | 01/2017 |
| End | 06/2020 |
| Description | Closed-loop insulin delivery in adults with type 2 diabetes receiving haemodialysis |
| Amount | £11,976 (GBP) |
| Organisation | Novo Nordisk |
| Sector | Private |
| Country | Denmark |
| Start | 08/2018 |
| End | 01/2020 |
| Description | Cox and Deegan - CiC project |
| Amount | £47,235 (GBP) |
| Funding ID | MC_PC_13059 |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Confidence in Concept Scheme |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2014 |
| End | 12/2014 |
| Description | DFG Fellowship |
| Amount | £85,500 (GBP) |
| Organisation | German Research Foundation |
| Sector | Charity/Non Profit |
| Country | Germany |
| Start | 10/2015 |
| End | 10/2017 |
| Description | DFG fellowship |
| Amount | £85,500 (GBP) |
| Organisation | German Research Foundation |
| Sector | Charity/Non Profit |
| Country | Germany |
| Start | |
| Description | Enhancement of lentiviral vector efficiency by modification of cis and trans acting factors affecting genomic RNA encapsidation |
| Amount | £32,000 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 09/2019 |
| Description | Evaluation of Peptides |
| Amount | £13,000 (GBP) |
| Organisation | Heptares Therapeutics Ltd |
| Sector | Private |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 02/2018 |
| Description | Fellowship for a postdoc |
| Amount | £34,031 (GBP) |
| Organisation | Federation of European Biochemical Societies (FEBS) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2016 |
| End | 01/2017 |
| Description | Follow on Funding |
| Amount | £150,000 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2014 |
| End | 02/2017 |
| Description | Follow-on Funding |
| Amount | £732,800 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 08/2018 |
| Description | GSK Biopharm Innovation Fund |
| Amount | £300,000 (GBP) |
| Organisation | GlaxoSmithKline (GSK) |
| Sector | Private |
| Country | Global |
| Start | 05/2014 |
| End | 05/2016 |
| Description | Genomic RNA control of HIV viral assembly and export |
| Amount | £386,860 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2016 |
| End | 07/2019 |
| Description | Guarantors of Brain Fellowship |
| Amount | £180,000 (GBP) |
| Organisation | Guarantors of Brain |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 12/2019 |
| Description | HEIF - Bridging |
| Amount | £120,000 (GBP) |
| Organisation | Higher Education Innovation Funding (HEIF) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Matched funding has been provided in the form of access to a GE In Cell Analyser 6000 at the SBC which was key to HCS of OPC differentiation and downstream analysis. |
| Amount | £115,000 (GBP) |
| Organisation | GE Healthcare Limited |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 06/2015 |
| Description | NIHR- EME |
| Amount | £1,300,000 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Novel apelin peptide agonists conjugated to AlbudAb antibody to increase plasma half-life |
| Amount | £323,037 (GBP) |
| Organisation | GlaxoSmithKline (GSK) |
| Sector | Private |
| Country | Global |
| Start | 12/2014 |
| End | 12/2017 |
| Description | Opportunities in Receptor Biology for Industrial Translation (Orbit) |
| Amount | £555,212 (GBP) |
| Organisation | Heptares Therapeutics Ltd |
| Sector | Private |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 12/2019 |
| Description | PET Markers of Oligomeric Misfolded Proteins in Neurodegenerative Disorders |
| Amount | £1,041,821 (GBP) |
| Funding ID | EP/P008224/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 12/2019 |
| Description | Project Grant |
| Amount | £240,106 (GBP) |
| Organisation | Diabetes UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2014 |
| End | 12/2016 |
| Description | Project Grants |
| Amount | £140,000 (GBP) |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2016 |
| End | 12/2018 |
| Description | SBC grant |
| Amount | £250,000 (GBP) |
| Organisation | Higher Education Funding Council for England |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2015 |
| End | 03/2017 |
| Description | Strategic Projects |
| Amount | £69,552 (GBP) |
| Organisation | Alzheimer's Research UK |
| Department | Alzheimers Research UK, Cambridge |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2013 |
| End | 09/2017 |
| Description | Super Follow on Funding |
| Amount | £732,800 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 08/2018 |
| Description | Unknown |
| Amount | $1,000,000 (USD) |
| Organisation | Stand up to Cancer |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | |
| Description | WT Pathfinder |
| Amount | £140,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2014 |
| End | 12/2015 |
| Description | Franklin |
| Organisation | GE Healthcare Limited |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | TBC |
| Collaborator Contribution | TBC |
| Impact | TBC |
| Start Year | 2014 |
| Description | MRCT- McNaughton |
| Organisation | MRC-Technology |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | TBC |
| Collaborator Contribution | TBC |
| Impact | TBC |
| Start Year | 2014 |
| Description | MTA - Rubinzstein |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Confidential |
| Collaborator Contribution | Confidential |
| Impact | n/a |
| Start Year | 2014 |
| Title | INHIBITION OF CXCR4 SIGNALING IN CANCER IMMUNOTHERAPY |
| Description | The inventions describes a method for increasing effector T cell accumulation in cancer cell-containing sites of a tumor, comprising administering to a subject in need thereof a pharmaceutically effective amount of an inhibitor of CXCR4 signaling |
| IP Reference | WO2015019284 |
| Protection | Patent application published |
| Year Protection Granted | 2015 |
| Licensed | Yes |
| Impact | Licensed to start up |
| Title | Aighbirhio |
| Description | TBC |
| Type | Support Tool - For Medical Intervention |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2014 |
| Development Status | Actively seeking support |
| Impact | TBC |
| Title | Cox |
| Description | Confidential |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Impact | TBC |
| Title | Davenport et al |
| Description | Confidential |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Impact | TBC |
| Title | Fearon & Jodrell |
| Description | Detail TBC - confidentiality unclear Stand up to cancer award obtained to fund clinical trial |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Impact | TBC |
| Title | Glen and Hiley |
| Description | Confidential |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Impact | TBC |
| Title | Hovorka |
| Description | Early Clinical Evaluation - Funded by Diabetes UK Dr Roman Hovorka will build on his successful research into an artificial pancreas for people with Type 1 diabetes to study its safety and effectiveness for the treatment of hospital inpatients with Type 2 diabetes Research aims Dr Roman Hovorka and his team will build on their successful studies of a prototype artificial pancreas for people with Type 1 diabetes to investigate its use for the management of Type 2 diabetes in hospital inpatients. The researchers will study the safety and effectiveness of the system in 20 inpatients with insulin-treated Type 2 diabetes over a 72-hour period. They will compare the results obtained to those achieved by 20 inpatients using conventional insulin injection therapy. As in previous trials, the artificial pancreas system will involve using a portable computer to link a continuous glucose sensor with an insulin pump - enabling them to talk intelligently to each other. The system will continuously measure glucose levels in the body and rapidly adjust the insulin dose provided to maintain these levels within a target range. |
| Type | Therapeutic Intervention - Medical Devices |
| Current Stage Of Development | Refinement. Clinical |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Impact | N/A |
| Title | Huntington's Disease Rilmenidine Safety Trial |
| Description | A first-of-its-kind trial has been published for Huntington's disease (HD). The trial was built on the pioneering work of David Rubinsztein who has shown that upregulating a process called autophagy (a process that helps clear rubbish out of cells) was good for treating HD in the lab. One of the agents that he had shown worked well was a drug called Rilmendine which has been used in the past to treat high blood pressure in people. The drug was given for two years, and found to be well tolerated and may have had some effect on the disease itself. More work is still being done and a further update will be given in the future. Read the paper here |
| Type | Therapeutic Intervention - Drug |
| Year Development Stage Completed | 2016 |
| Development Status | Actively seeking support |
| Clinical Trial? | Yes |
| Impact | One of the agents that he had shown worked well was a drug called Rilmendine which has been used in the past to treat high blood pressure in people. The drug was given for two years, and found to be well tolerated and may have had some effect on the disease itself. More work is still being done and a further update will be given in the future. Read the paper here |
| URL | https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-018119-14 |
| Title | McNaughton & Cavalla |
| Description | Confidential Under development |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Impact | none yet |
| Title | Neal and Spring |
| Description | Confidential |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Impact | TBC |
| Description | BartsMS Blog |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | MS life 2014 Myelin Repair-using stem cells from within |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://multiple-sclerosis-research.blogspot.com/2014/05/ms-life-2014-myelin-repair-using-stem.html |
| Description | INVITED RESEARCHER: ROBIN FRANKLIN, "REINFORCING REMYELINATION" |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Robin Franklin, Professor of Stem Cell Medicine at the University of Cambridge, was invited to the ICM on September 28, 2015 to present his work on remyelination of cells in the central nervous system and a therapeutic approach proposed to address certain neurodegenerative disorders such as multiple sclerosis. |
| Year(s) Of Engagement Activity | 2015 |
| URL | https://icm-institute.org/en/actualite/invited-researcher-robin-franklin-reinforcing-remyelination/ |
| Description | MS Research Talks - Day 2 - Live from MS Life 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | MS Society Streamed live on Sep 18, 2016 Live research talks from the MS Life 2016 theatre. Myelin Repair: Prof Robin Franklin, University of Cambridge |
| Year(s) Of Engagement Activity | 2006,2016 |
| URL | https://www.youtube.com/watch?v=NS_2n7Rw7CQ |
| Description | MS life 2014 Myelin Repair-using stem cells from within |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | One approach is to make stem cells that are present in the MS actually work properly |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://multiple-sclerosis-research.blogspot.com/2014/05/ms-life-2014-myelin-repair-using-stem.html |
| Description | Reinforcing remyelination |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Robin Franklin, Professor of Stem Cell Medicine at the University of Cambridge, was invited to the ICM on September 28, 2015 to present his work on remyelination of cells in the central nervous system and a therapeutic approach proposed to address certain neurodegenerative disorders such as multiple sclerosis. |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://icm-institute.org/en/actualite/invited-researcher-robin-franklin-reinforcing-remyelination |